Edition:
India

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

75.60CHF
15 Jun 2018
Change (% chg)

CHF0.10 (+0.13%)
Prev Close
CHF75.50
Open
CHF75.82
Day's High
CHF76.14
Day's Low
CHF75.60
Volume
13,747,991
Avg. Vol
5,362,340
52-wk High
CHF88.30
52-wk Low
CHF72.68

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.05
Market Cap(Mil.): CHF219,900.80
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.75
Yield (%): 3.27

Financials

  NOVN.S Industry Sector
P/E (TTM): 31.37 30.95 32.74
EPS (TTM): 2.68 -- --
ROI: 6.14 14.84 14.38
ROE: 9.19 16.34 16.08

Novartis touts effectiveness, safety of autoimmune drug copies

ZURICH Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson & Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases.

15 Jun 2018

Novartis touts effectiveness, safety of autoimmune drug copies

ZURICH, June 15 Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson & Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases. The Swiss drugmaker said Zessly, its Remicade biosimilar, matched the original medicine for safety and efficacy at 54 weeks, including in patients who switched from the original. Switching from

15 Jun 2018

Novartis readies anti-sexism message for migraine drug

ZURICH With women hardest hit by migraine headaches, Swiss drugmaker Novartis is gearing up its marketing message to counteract sexism that it worries might become a barrier to adoption of its new medicine Aimovig. 

02 Jun 2018

UPDATE 1-Novartis readies anti-sexism message for migraine drug

* Swiss company also considering new pricing models (Recasts story to focus on Novartis strategy, adds comment from chief neurological developer, details throughout)

01 Jun 2018

Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod

ZURICH Novartis's generics unit on Friday won a European panel's recommendation for its biosimilar version of AbbVie's Humira as the Swiss drugmaker aims to take a bite out of sales of one of the world's best-selling medicines.

01 Jun 2018

Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod

ZURICH, June 1 Novartis's generics unit on Friday won a European panel's recommendation for its biosimilar version of AbbVie's Humira as the Swiss drugmaker aims to take a bite out of sales of one of the world's best-selling medicines.

01 Jun 2018

Novartis wins key European panel's thumbs-up for migraine drug

June 1 Novartis's new migraine drug Aimovig won a key recommendation from a key European panel on Friday, helping open the way for potential sales before the end of the year for a medicine the Swiss drugmaker is counting on to boost growth.

01 Jun 2018

Novartis receives EU approval for biosimilar Zessly

ZURICH Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases.

24 May 2018

Novartis receives EU approval for biosimilar Zessly

ZURICH, May 24 Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases.

24 May 2018

BRIEF-Novartis, Amgen Announce FDA Approval Of Aimovig Treatment For Migraine Prevention

* NOVARTIS AND AMGEN ANNOUNCE FDA APPROVAL OF AIMOVIG™ (ERENUMAB-AOOE), A NOVEL TREATMENT DEVELOPED SPECIFICALLY FOR MIGRAINE PREVENTION

18 May 2018

Earnings vs. Estimates